Literature DB >> 11240035

The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls.

C G Haase1, J Guggenmos, U Brehm, M Andersson, T Olsson, M Reindl, J M Schneidewind, U K Zettl, F Heidenreich, T Berger, H Wekerle, R Hohlfeld, C Linington.   

Abstract

Antibodies directed against the extracellular immunoglobulin (Ig)-like domain of the myelin oligodendrocyte glycoprotein (MOG(Igd)) mediate demyelination in experimental autoimmune encephalomyelitis (EAE) and are implicated in the immunopathogenesis of multiple sclerosis (MS). In this study we investigated the epitope specificity of MOG(Igd)-specific autoantibodies immunopurified from MS patients (n=17) and normal healthy controls (HD; n=9). ELISA, using a panel of synthetic MOG(Igd) peptides, revealed that the epitope specificity of this response was heterogeneous in both groups. The most frequently recognised epitopes were located in amino acid sequences (a.a.) 1-26 (13/17) and 63-87 (15/17) in MS patients, and 14-39 (6/9) and 63-87 (6/9) in HDs, but there was no association between MS and any particular peptide specificity. We therefore investigated the ability of the immunopurified antibodies to recognise native MOG(Igd) expressed on at the membrane surface by FACS. Unexpectedly, antibodies fulfilling this essential criterion for a demyelinating antibody response were detected only in one of the MS samples. These results indicate that the epitope specificity of the human B cell response to MOG is not only heterogeneous, but may only mediate demyelination in a limited subset of MS patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11240035     DOI: 10.1016/s0165-5728(00)00462-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  24 in total

1.  Gene-expression profiling of experimental autoimmune encephalomyelitis.

Authors:  Eilhard Mix; Jens Pahnke; Saleh M Ibrahim
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

2.  Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Maria V Tejada-Simon; Jian Hong; Victor M Rivera; Jingwu Z Zhang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

Review 4.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 5.  Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice.

Authors:  Amanda Marchionatti; Mark Woodhall; Patrick Joseph Waters; Douglas Kazutoshi Sato
Journal:  Neurol Sci       Date:  2020-10-15       Impact factor: 3.307

6.  Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology.

Authors:  Cecilia B Marta; Alfred R Oliver; Rebecca A Sweet; Steven E Pfeiffer; Nancy H Ruddle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

7.  Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Dun Zhou; Rajneesh Srivastava; Stefan Nessler; Verena Grummel; Norbert Sommer; Wolfgang Brück; Hans-Peter Hartung; Christine Stadelmann; Bernhard Hemmer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

8.  Myelin Oligodendrocyte Glycoprotein-IgG Contributes to Oligodendrocytopathy in the Presence of Complement, Distinct from Astrocytopathy Induced by AQP4-IgG.

Authors:  Ling Fang; Xinmei Kang; Zhen Wang; Shisi Wang; Jingqi Wang; Yifan Zhou; Chen Chen; Xiaobo Sun; Yaping Yan; Allan G Kermode; Lisheng Peng; Wei Qiu
Journal:  Neurosci Bull       Date:  2019-04-30       Impact factor: 5.203

Review 9.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

Review 10.  B cells in multiple sclerosis.

Authors:  Mark P Burgoon; Donald H Gilden; Gregory P Owens
Journal:  Front Biosci       Date:  2004-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.